Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL Short title: B-ALLs are sensitive to an HDAC1/HDAC2 inhibitor

1 Division of Hematology/Oncology, Boston Children’s Hospital, Department of Pediatric Oncology, Dana-Farber-Cancer Institute, and Harvard Medical School, Boston, MA, USA 2 Department of Medical Oncology, Dana-Farber-Cancer Institute and Harvard Medical School, Boston, MA, USA 3 Harvard Stem Cell Institute, Boston, MA, USA 4 Current affiliation – Incyte Corporation, Wilmington, DE 5 Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY Corresponding Author: Matthew C. Stubbs Phone: 302-498-5716 Fax : 302-425-2759 Email: [email protected] Address: Incyte Corporation 1801 Augustine Cut-off Wilmington, DE 19803